See more : Halla Corporation (014790.KS) Income Statement Analysis – Financial Results
Complete financial analysis of Sera Prognostics, Inc. (SERA) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Sera Prognostics, Inc., a leading company in the Medical – Diagnostics & Research industry within the Healthcare sector.
You may be interested
- Retail Estates N.V. (RET.BR) Income Statement Analysis – Financial Results
- Namkwang Engineering & Construction Co., Ltd. (001260.KS) Income Statement Analysis – Financial Results
- Berkshire Hills Bancorp, Inc. (BHLB) Income Statement Analysis – Financial Results
- Spree Acquisition Corp. 1 Limited (SHAP-UN) Income Statement Analysis – Financial Results
- Qifu Technology, Inc. (QFIN) Income Statement Analysis – Financial Results
Sera Prognostics, Inc. (SERA)
About Sera Prognostics, Inc.
Sera Prognostics, Inc., a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in asymptomatic singleton pregnancies. It is also developing a portfolio of product candidates for various pregnancy-related conditions, including preeclampsia, molecular time-to-birth, gestational diabetes mellitus, fetal growth restriction, stillbirth, and postpartum depression. The company was incorporated in 2008 and is headquartered in Salt Lake City, Utah.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 306.00K | 268.00K | 82.00K | 25.00K | 36.00K |
| Cost of Revenue | 210.00K | 193.00K | 37.00K | 11.00K | 18.00K |
| Gross Profit | 96.00K | 75.00K | 45.00K | 14.00K | 18.00K |
| Gross Profit Ratio | 31.37% | 27.99% | 54.88% | 56.00% | 50.00% |
| Research & Development | 15.23M | 14.24M | 11.02M | 7.78M | 9.35M |
| General & Administrative | 16.34M | 16.78M | 14.09M | 6.56M | 4.28M |
| Selling & Marketing | 8.35M | 14.70M | 10.33M | 3.65M | 2.96M |
| SG&A | 24.69M | 31.48M | 24.42M | 10.20M | 7.24M |
| Other Expenses | 0.00 | 1.53M | 1.13M | -80.00K | -17.00K |
| Operating Expenses | 39.92M | 45.73M | 35.44M | 17.99M | 16.58M |
| Cost & Expenses | 40.13M | 45.92M | 35.48M | 18.00M | 16.60M |
| Interest Income | 1.64M | 456.00K | 145.00K | 42.00K | 64.00K |
| Interest Expense | 55.00K | 61.00K | 746.00K | 1.84M | 1.97M |
| Depreciation & Amortization | 900.00K | 1.22M | 659.00K | 895.00K | 946.00K |
| EBITDA | -35.29M | -42.91M | -33.60M | -17.11M | -13.60M |
| EBITDA Ratio | -11,531.70% | -16,464.55% | -41,784.15% | -68,456.00% | -37,786.11% |
| Operating Income | -39.82M | -45.65M | -35.40M | -17.97M | -16.56M |
| Operating Income Ratio | -13,013.40% | -17,034.33% | -43,164.63% | -71,884.00% | -45,997.22% |
| Total Other Income/Expenses | 3.58M | 1.47M | 386.00K | -1.88M | 55.00K |
| Income Before Tax | -36.24M | -44.19M | -35.01M | -19.85M | -16.52M |
| Income Before Tax Ratio | -11,843.79% | -16,487.31% | -42,693.90% | -79,392.00% | -45,891.67% |
| Income Tax Expense | 0.00 | 61.00K | 1.22M | 1.76M | 3.92M |
| Net Income | -36.24M | -44.25M | -36.23M | -21.61M | -20.44M |
| Net Income Ratio | -11,843.79% | -16,510.07% | -44,180.49% | -86,428.00% | -56,775.00% |
| EPS | -1.16 | -1.43 | -1.18 | -0.70 | -0.67 |
| EPS Diluted | -1.16 | -1.43 | -1.18 | -0.70 | -0.67 |
| Weighted Avg Shares Out | 31.20M | 30.94M | 30.77M | 30.70M | 30.70M |
| Weighted Avg Shares Out (Dil) | 31.20M | 30.94M | 30.77M | 30.70M | 30.70M |
Sera Prognostics, Inc. (SERA) Q3 2022 Earnings Call Transcript
Sera Prognostics, Inc. (NASDAQ:SERA ) Q3 2022 Earnings Conference Call November 9, 2022 5:00 PM ET Company Participants Peter DeNardo - CapComm Partners, IR Greg Critchfield - President and CEO Jay Moyes - CFO Conference Call Participants Patrick Donnelly -...
Sera Prognostics, Inc. (SERA) Reports Q3 Loss, Tops Revenue Estimates
Sera Prognostics, Inc. (SERA) delivered earnings and revenue surprises of 12.50% and 2.35%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Sera Prognostics, Inc. (SERA) CEO Greg Critchfield on Q2 2022 Results - Earnings Call Transcript
Sera Prognostics, Inc. (NASDAQ:SERA ) Q2 2022 Earnings Conference Call August 10, 2022 5:00 PM ET Company Participants Peter DeNardo - CapComm Partners Greg Critchfield - Chairman, President & Chief Executive Officer Jay Moyes - Chief Financial Officer Conference Call...
Sera Prognostics, Inc. (SERA) Reports Q2 Loss, Lags Revenue Estimates
Sera Prognostics, Inc. (SERA) delivered earnings and revenue surprises of 7.50% and 22%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
A Negative EV Opportunity - Sera Prognostics Has A Chance To Become Standard Of Care In Preterm Birth Risk Screening
SERA sells PreTRM®, a CLIA-lab based assay to determine the risk of a woman having a pre-term birth – a birth prior to 37 weeks of gestation. After IPO'ing in July 2021 at $16, the Company has since lost over...
SERA PROGNOSTICS TO PRESENT AT 42nd ANNUAL WILLIAM BLAIR GROWTH STOCK CONFERENCE
SALT LAKE CITY , June 6, 2022 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that the company will present...
Sera Prognostics, Inc. (SERA) CEO Greg Critchfield on Q1 2022 Results - Earnings Call Transcript
Sera Prognostics, Inc. (NASDAQ:SERA ) Q1 2022 Earnings Conference Call May 10, 2022 5:00 PM ET Company Participants Peter DeNardo - Investor Relations Greg Critchfield - Chairman, President and Chief Executive Officer Jay Moyes - Chief Financial Officer Conference Call...
Sera Prognostics Announces Conference Call and Webcast of First Quarter Fiscal Year 2022 Financial Results on May 10
SALT LAKE CITY , May 2, 2022 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that it will report first...
Sera Prognostics, Inc. (SERA) CEO Gregory Critchfield on Q4 2021 Earnings Call Transcript
Sera Prognostics, Inc. (SERA) CEO Gregory Critchfield on Q4 2021 Earnings Call Transcript
Sera Prognostics Announces Conference Call and Webcast of Fourth Quarter and Fiscal Year 2021 Financial Results on March 29
SALT LAKE CITY , March 18, 2022 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that it will report fourth...
Source: https://incomestatements.info
Category: Stock Reports